HeartBeam Toekomstige groei
Future criteriumcontroles 5/6
De verwachting is dat HeartBeam de winst en omzet met respectievelijk 55.4% en 57.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 36.3% per jaar.
Belangrijke informatie
55.4%
Groei van de winst
36.28%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.3% |
| Inkomstengroei | 57.8% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 14 Aug 2026 |
Recente toekomstige groei-updates
Recent updates
BEAT: Funding Runway Extension Will Support Commercial Execution And Future Upside Potential
Analysts have reset their HeartBeam price expectations lower, with the average target moving from about $8 to about $5 as they factor in a slower than previously modeled revenue ramp, modestly softer margin assumptions, some dilution from the recent $11.5m equity raise at $0.80 per share, and new coverage that still frames the stock as a higher risk and higher P/E opportunity within its space. Analyst Commentary on HeartBeam Recent Street research on HeartBeam highlights a mix of caution on execution timing and continued interest in the stock's long term potential.
BEAT: Slower Commercial Ramp And Dilution Will Set Up Future Rebound
Analysts now place their average price target for HeartBeam closer to $2.00 from $2.50, reflecting expectations for a slower pace of revenue scaling and potential dilution effects, even as recent research updates continue to describe the Q1 progress and funding runway in constructive terms. Analyst Commentary Recent Street commentary around HeartBeam has shifted toward a more cautious tone, with several bearish analysts recalibrating expectations on revenue timing, funding effects, and the risk that execution may lag earlier assumptions.BEAT: Slower Commercial Ramp Will Set Up Future Rebound After Recent Dilution
HeartBeam's updated analyst price target has shifted from $4.00 to $2.50 as analysts factor in expectations for a slower revenue ramp, modestly adjusted profit margins, and a higher future P/E, partly influenced by recent equity dilution and revised sales timelines following the Q1 update. Analyst Commentary Recent Street research on HeartBeam points to a more cautious tone, with several bearish analysts recalibrating their expectations after the Q1 update.
BEAT: Extended Funding Runway Will Support Longer Commercialization Ramp
HeartBeam's updated analyst price targets, which have shifted lower from prior levels such as $8 to $5 and $5.50 to $2.50, reflect analysts' expectations for a longer revenue ramp and the impact of recent equity dilution on fair value and profit margin assumptions. Analyst Commentary Recent Street research on HeartBeam presents a mixed picture, with analysts balancing expectations for a slower revenue ramp and share dilution against a constructive view on the company’s longer term execution potential.Concierge Cardiac Care And AI Collaboration Will Shape A Long Term Bullish View
Catalysts About HeartBeam HeartBeam develops portable, cable free 12 lead ECG technology for at home and ambulatory cardiac assessment. What are the underlying business or industry changes driving this perspective?At Home ECG Clearances And AI Pipeline Will Transform Cardiac Care Over Time
Catalysts About HeartBeam HeartBeam develops portable, cable free ECG technology that lets patients capture clinical grade 12 lead readings at home or on demand. What are the underlying business or industry changes driving this perspective?Home Cardiac Diagnostics And AI Delays Will Restrain Progress Yet Eventually Support Potential Upside
Catalysts About HeartBeam HeartBeam develops a portable, cable free ECG system intended to give patients at home clinical grade 12 lead readings supported by remote cardiologist review. What are the underlying business or industry changes driving this perspective?Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...HeartBeam gets a new chief medical officer
HeartBeam (NASDAQ:BEAT) appoints renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He has also been a consultant to the US Food and Drug Administration for the past 20 years, focused on medical technology and data driven health analytics. Shares are up 2.37% premarket.HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%
HeartBeam (NASDAQ:BEAT) on Wednesday said it had been issued a patent from the U.S. Patent and Trademark Office which enables it to generate its credit card-sized AIMIGo 12-lead electrocardiogram (ECG) for the detection of heart attacks. Shares of the company rose 14.5% to $3.08 in early trading. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” BEAT CEO Branislav Vajdic said in a statement. The newly issued patent - No. 11,445,963 B2 - expands on BEAT's granted and pending core patents for remote heart attack detection, the company said.HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks
HeartBeam (NASDAQ:BEAT) is trading 54% higher premarket after it received patent for a 12-lead electrocardiogram (ECG) patch monitor to detect acute coronary syndrome and cardiac arrhythmia by the United States Patent and Trademark Office. The company expects its ECG device to detect ACS diagnosis including myocardial infarction (heart attack) and angina. The newly issued patent expands on the HeartBeam’s previously granted US patent for a 12-lead ECG patch monitor technology. The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks. Stock has been down ~66% YTD.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 16 | -8 | N/A | -8 | 3 |
| 12/31/2027 | 5 | -19 | N/A | -12 | 4 |
| 12/31/2026 | 1 | -19 | N/A | -13 | 1 |
| 6/30/2026 | N/A | -20 | -14 | -13 | N/A |
| 3/31/2026 | N/A | -20 | -14 | -13 | N/A |
| 12/31/2025 | N/A | -21 | -15 | -14 | N/A |
| 9/30/2025 | N/A | -21 | -15 | -15 | N/A |
| 6/30/2025 | N/A | -20 | -16 | -15 | N/A |
| 3/31/2025 | N/A | -20 | -16 | -15 | N/A |
| 12/31/2024 | N/A | -19 | -15 | -14 | N/A |
| 9/30/2024 | N/A | -18 | -13 | -13 | N/A |
| 6/30/2024 | N/A | -17 | -12 | -12 | N/A |
| 3/31/2024 | N/A | -15 | -13 | -12 | N/A |
| 12/31/2023 | N/A | -15 | -12 | -12 | N/A |
| 9/30/2023 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2023 | N/A | -15 | -13 | -13 | N/A |
| 3/31/2023 | N/A | -15 | -11 | -11 | N/A |
| 12/31/2022 | N/A | -13 | -10 | -10 | N/A |
| 9/30/2022 | N/A | -11 | -9 | -9 | N/A |
| 6/30/2022 | N/A | -9 | -7 | -7 | N/A |
| 3/31/2022 | N/A | -6 | -5 | -5 | N/A |
| 12/31/2021 | N/A | -4 | -3 | -3 | N/A |
| 9/30/2021 | N/A | -3 | -1 | -1 | N/A |
| 6/30/2021 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2021 | N/A | -1 | -1 | -1 | N/A |
| 12/31/2020 | N/A | -1 | -1 | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat BEAT de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.7% ).
Winst versus markt: Er wordt verwacht dat BEAT de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat BEAT binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van BEAT ( 57.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 13% per jaar).
Hoge groei-inkomsten: De omzet van BEAT ( 57.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van BEAT naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/16 07:12 |
| Aandelenkoers aan het einde van de dag | 2026/08/14 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
HeartBeam, Inc. wordt gevolgd door 5 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| William Sutherland | Benchmark Company |
| Anderson Schock | B. Riley Securities, Inc. |